Regeneron Autoimmune Disease Antibody Compositions Patent EP3980066A1
Summary
The EPO published patent application EP3980066A1 by Regeneron Pharmaceuticals covering methods and compositions for treating autoimmune diseases using antibody-based therapeutics. The application claims compositions targeting immune pathways including A61P 37/02 and A61P 37/06 classifications. The patent designates all EU member states plus several additional European countries.
What changed
The EPO published Regeneron Pharmaceuticals' patent application EP3980066A1, titled 'Methods and Compositions for Treating Autoimmune Diseases,' covering therapeutic antibody compositions and methods of use. The application claims compositions including antibodies targeting immune pathways (A61K 39/395, C07K 16/28) for treating autoimmune conditions.
Pharmaceutical manufacturers and biotechnology companies developing autoimmune disease therapies should review this patent for freedom-to-operate implications in EU markets. The patent's broad designation of all EU member states creates potential blocking positions for competing therapeutic approaches. Competitors should assess whether their development programs may infringe these claims or whether design-around strategies are warranted.
What to do next
- Monitor patent register for related divisional or continuation applications
- Review Freedom to Operate for autoimmune disease therapeutics in EU markets
- Track any oppositions or limitations filed against EP3980066A1
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES
Publication EP3980066A1 Kind: A1 Apr 01, 2026
Applicants
Regeneron Pharmaceuticals, Inc.
Inventors
GILLARD, Geoffrey O., PROCTOR, Jennifer Lynn, BOITANO, Anthony, COOKE, Michael
IPC Classifications
A61K 39/395 20060101AFI20230626BHEP A61K 47/68 20170101ALI20230626BHEP A61P 37/02 20060101ALI20230626BHEP A61P 37/06 20060101ALI20230626BHEP C07K 16/28 20060101ALI20230626BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.